{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:09:49Z","timestamp":1792123789503,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelofibrosis is a BCR-ABL1\u2013negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase\/signal transducers and activators of transcription (JAK-STAT) pathway, and other cellular pathways downstream, leads to myeloproliferation, proinflammatory cytokine expression, and bone marrow remodeling. Transplant is the only curative option for myelofibrosis, but high rates of morbidity and mortality limit eligibility. Several prognostic models have been developed to facilitate treatment decisions. Until the recent approval of fedratinib, a JAK2 inhibitor, ruxolitinib was the only available JAK inhibitor for treatment of intermediate- or high-risk myelofibrosis. Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib due to dose-dependent drug-related cytopenias, and even patients with a good initial response often develop resistance to ruxolitinib after 2\u20133\u00a0years of therapy. Currently, there is no consensus definition of ruxolitinib <jats:italic>failure<\/jats:italic>. Until fedratinib approval, strategies to overcome ruxolitinib resistance or intolerance were mainly different approaches to continued ruxolitinib therapy, including dosing modifications and ruxolitinib rechallenge. Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to induce clinical responses and improve symptoms in patients previously treated with ruxolitinib. Fedratinib induces robust spleen responses, and pacritinib and momelotinib may have preferential activity in patients with severe cytopenias. Reviewed here are strategies to ameliorate ruxolitinib resistance or intolerance, and outcomes of clinical trials in patients with myelofibrosis receiving second-line JAK inhibitors after ruxolitinib treatment.<\/jats:p>","DOI":"10.1007\/s00277-020-04002-9","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T09:07:55Z","timestamp":1584695275000},"page":"1177-1191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Management of myelofibrosis after ruxolitinib failure"],"prefix":"10.1007","volume":"99","author":[{"given":"Claire N","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"issue":"12","key":"4002_CR1","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/ajh.24592","volume":"91","author":"A Tefferi","year":"2016","unstructured":"Tefferi A (2016) Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 91(12):1262\u20131271. https:\/\/doi.org\/10.1002\/ajh.24592","journal-title":"Am J Hematol"},{"issue":"8","key":"4002_CR2","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kroger N, Thiele J, Barbui T, Barosi G (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395\u20131398. https:\/\/doi.org\/10.1182\/blood-2013-03-488098","journal-title":"Blood"},{"issue":"1","key":"4002_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/asheducation-2016.1.552","volume":"2016","author":"JM Shammo","year":"2016","unstructured":"Shammo JM, Stein BL (2016) Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions. Hematology Am Soc Hematol Educ Program 2016(1):552\u2013560. https:\/\/doi.org\/10.1182\/asheducation-2016.1.552","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"4002_CR4","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27(9):1861\u20131869. https:\/\/doi.org\/10.1038\/leu.2013.119","journal-title":"Leukemia"},{"issue":"4","key":"4002_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1053\/j.seminhematol.2018.05.013","volume":"55","author":"F Palandri","year":"2018","unstructured":"Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D\u2019Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N (2018) Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. Semin Hematol 55(4):248\u2013255. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.05.013","journal-title":"Semin Hematol"},{"issue":"5","key":"4002_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.bjhh.2014.10.001","volume":"37","author":"RM de Freitas","year":"2015","unstructured":"de Freitas RM, da Costa Maranduba CM (2015) Myeloproliferative neoplasms and the JAK\/STAT signaling pathway: an overview. Rev Bras Hematol Hemoter 37(5):348\u2013353. https:\/\/doi.org\/10.1016\/j.bjhh.2014.10.001","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"2","key":"4002_CR7","first-page":"121","volume":"16","author":"JM O\u2019Sullivan","year":"2018","unstructured":"O\u2019Sullivan JM, Harrison CN (2018) Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol 16(2):121\u2013131","journal-title":"Clin Adv Hematol Oncol"},{"issue":"13","key":"4002_CR8","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"9","key":"4002_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703\u20131708. https:\/\/doi.org\/10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"issue":"4","key":"4002_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392\u2013397. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol"},{"issue":"3","key":"4002_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16(3):358\u2013367. https:\/\/doi.org\/10.1016\/j.bbmt.2009.10.025","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4002_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1182\/asheducation-2016.1.543","volume":"2016","author":"R Devlin","year":"2016","unstructured":"Devlin R, Gupta V (2016) Myelofibrosis: to transplant or not to transplant? Hematology Am Soc Hematol Educ Program 2016(1):543\u2013551. https:\/\/doi.org\/10.1182\/asheducation-2016.1.543","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"21","key":"4002_CR13","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","volume":"125","author":"N Kroger","year":"2015","unstructured":"Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg HJ, Passamonti F (2015) Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 125(21):3347\u20133350; quiz 3364. https:\/\/doi.org\/10.1182\/blood-2014-10-608315","journal-title":"Blood"},{"issue":"4","key":"4002_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A (2018) MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36(4):310\u2013318. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886","journal-title":"J Clin Oncol"},{"issue":"3","key":"4002_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.24978","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi AM (2018) Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol 93(3):348\u2013355. https:\/\/doi.org\/10.1002\/ajh.24978","journal-title":"Am J Hematol"},{"issue":"17","key":"4002_CR16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM (2018) MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol 36(17):1769\u20131770. https:\/\/doi.org\/10.1200\/JCO.2018.78.9867","journal-title":"J Clin Oncol"},{"issue":"7","key":"4002_CR17","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema G, Pardanani A, Vannucchi AM (2018) GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32(7):1631\u20131642. https:\/\/doi.org\/10.1038\/s41375-018-0107-z","journal-title":"Leukemia"},{"issue":"20","key":"4002_CR18","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Socie G, Beelen D, Triviai I, Badbaran A, Kroger N (2019) Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 133(20):2233\u20132242. https:\/\/doi.org\/10.1182\/blood-2018-12-890889","journal-title":"Blood"},{"issue":"1","key":"4002_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2040620712461047","volume":"4","author":"MB Sonbol","year":"2013","unstructured":"Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV (2013) Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 4(1):15\u201335. https:\/\/doi.org\/10.1177\/2040620712461047","journal-title":"Ther Adv Hematol"},{"key":"4002_CR20","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1038\/bcj.2014.84","volume":"4","author":"A Pardanani","year":"2014","unstructured":"Pardanani A, Tefferi A (2014) Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J 4:e268. https:\/\/doi.org\/10.1038\/bcj.2014.84","journal-title":"Blood Cancer J"},{"issue":"22","key":"4002_CR21","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/blood-2018-01-791491","volume":"131","author":"F Passamonti","year":"2018","unstructured":"Passamonti F, Maffioli M (2018) The role of JAK2 inhibitors in MPNs 7 years after approval. Blood 131(22):2426\u20132435. https:\/\/doi.org\/10.1182\/blood-2018-01-791491","journal-title":"Blood"},{"key":"4002_CR22","unstructured":"Jakafi\u00ae (ruxolitinib) prescribing information. Incyte Corporation, Wilmington, DE. Rev 05\/2019. Available at: https:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf. Accessed June 19, 2018"},{"issue":"9","key":"4002_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"issue":"9","key":"4002_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"8","key":"4002_CR25","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30(8):1701\u20131707. https:\/\/doi.org\/10.1038\/leu.2016.148","journal-title":"Leukemia"},{"issue":"1","key":"4002_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, investigators C-I (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55. https:\/\/doi.org\/10.1186\/s13045-017-0417-z","journal-title":"J Hematol Oncol"},{"issue":"Suppl 1","key":"4002_CR27","doi-asserted-by":"publisher","first-page":"abstract 4277","DOI":"10.1182\/blood-2018-99-116289","volume":"132","author":"F Palandri","year":"2018","unstructured":"Palandri F, Elli EM, Polverelli N, Bonifacio M, Benevolo G, Abruzzese E, Bergamaschi M, Tieghi A, Iurlo A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Latagliata R, Auteri G, Scaffidi L, Cattaneo D, Catani L, Krampera M, Vitolo U, Aversa F, Lemoli RM, Cuneo A, Semenzato G, Foa R, Di Raimondo F, Cavo M, Bartoletti D, Vianelli N, Breccia M, Palumbo GA (2018) Outcome of patients with myelofibrosis after ruxolitinib failure: role of disease status and treatment strategies in 214 patients. Blood 132(Suppl 1):abstract 4277","journal-title":"Blood"},{"issue":"3","key":"4002_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","volume":"97","author":"AT Kuykendall","year":"2018","unstructured":"Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS (2018) Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol 97(3):435\u2013441. https:\/\/doi.org\/10.1007\/s00277-017-3194-4","journal-title":"Ann Hematol"},{"key":"4002_CR29","doi-asserted-by":"publisher","first-page":"abstract 2833","DOI":"10.1182\/blood.V122.21.2833.2833","volume":"122","author":"E Fonseca","year":"2013","unstructured":"Fonseca E, Silver RT, Kazis LE, Iqbal SU, Rose M, Khan N (2013) Ruxolitinib discontinuation in patients with myelofibrosis: an analysis from clinical practice. Blood 122:abstract 2833","journal-title":"Blood"},{"issue":"9","key":"4002_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","volume":"130","author":"KJ Newberry","year":"2017","unstructured":"Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S (2017) Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125\u20131131. https:\/\/doi.org\/10.1182\/blood-2017-05-783225","journal-title":"Blood"},{"issue":"3","key":"4002_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","volume":"22","author":"M Shanavas","year":"2016","unstructured":"Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V (2016) Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1\/2 inhibitors. Biol Blood Marrow Transplant 22(3):432\u2013440. https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.005","journal-title":"Biol Blood Marrow Transplant"},{"key":"4002_CR32","unstructured":"INREBIC\u00ae (fedratinib) prescribing information. Impact Biomedicines, Inc., Summit, NJ; Rev 08\/2019"},{"issue":"7","key":"4002_CR33","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S2352-3026(17)30102-3","volume":"4","author":"HM Kvasnicka","year":"2017","unstructured":"Kvasnicka HM (2017) How to define treatment failure for JAK inhibitors. Lancet Haematol 4(7):e305\u2013e306. https:\/\/doi.org\/10.1016\/S2352-3026(17)30102-3","journal-title":"Lancet Haematol"},{"issue":"7","key":"4002_CR34","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/s2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, W inton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA (2017) Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4(7):e317\u2013e324. https:\/\/doi.org\/10.1016\/s2352-3026(17)30088-1","journal-title":"Lancet Haematol"},{"issue":"2","key":"4002_CR35","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5(2):e73\u2013e81. https:\/\/doi.org\/10.1016\/S2352-3026(17)30237-5","journal-title":"Lancet Haematol"},{"issue":"5","key":"4002_CR36","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S (2018) Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 4(5):652\u2013659. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5818","journal-title":"JAMA Oncol"},{"key":"4002_CR37","doi-asserted-by":"publisher","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladijan JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA (2020) Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25777","DOI":"10.1002\/ajh.25777"},{"issue":"11","key":"4002_CR38","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/j.clml.2018.06.025","volume":"18","author":"A Gerds","year":"2018","unstructured":"Gerds A, Su D, Martynova A, Pannell B, Mukherjee S, O\u2019Neill C, Sekeres M, O\u2019Connell C (2018) Ruxolitinib rechallenge can improve constitutional symptoms and splenomegaly in patients with myelofibrosis: a case series. Clin Lymphoma Myeloma Leuk 18(11):e463\u2013e468. https:\/\/doi.org\/10.1016\/j.clml.2018.06.025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"4002_CR39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A (2015) Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 1(5):643\u2013651. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1590","journal-title":"JAMA Oncol"},{"issue":"34","key":"4002_CR40","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J (2017) SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 35(34):3844\u20133850. https:\/\/doi.org\/10.1200\/JCO.2017.73.4418","journal-title":"J Clin Oncol"},{"issue":"5","key":"4002_CR41","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN (2017) Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol 4(5):e225\u2013e236. https:\/\/doi.org\/10.1016\/S2352-3026(17)30027-3","journal-title":"Lancet Haematol"},{"issue":"9","key":"4002_CR42","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, Investigators C (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100(9):1139\u20131145. https:\/\/doi.org\/10.3324\/haematol.2014.119545","journal-title":"Haematologica"},{"issue":"3","key":"4002_CR43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.12985","volume":"167","author":"JT Reilly","year":"2014","unstructured":"Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN (2014) Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology guidelines for investigation and management of myelofibrosis 2012. Br J Haematol 167(3):418\u2013420. https:\/\/doi.org\/10.1111\/bjh.12985","journal-title":"Br J Haematol"},{"key":"4002_CR44","unstructured":"National Comprehensive Cancer Network (2019) NCCN clinical practice guidelines in oncology\u2014myeloproliferative neoplasms v3.2020"},{"key":"4002_CR45","doi-asserted-by":"publisher","first-page":"abstract 1128","DOI":"10.1182\/blood.V128.22.1128.1128","volume":"128","author":"F Palandri","year":"2016","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D\u2019Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, De Marchi EC, Anaclerico B, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Cavo M, Vianelli N, Breccia M (2016) Predictors for response to ruxolitinib in real-life: an observational independent study on 408 patients with myelofibrosis. Blood 128:abstract 1128","journal-title":"Blood"},{"issue":"6","key":"4002_CR46","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","volume":"126","author":"KP Patel","year":"2015","unstructured":"Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S (2015) Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790\u2013797. https:\/\/doi.org\/10.1182\/blood-2015-03-633404","journal-title":"Blood"},{"issue":"1","key":"4002_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-018-0642-0","volume":"11","author":"M Talpaz","year":"2018","unstructured":"Talpaz M, Erickson-Viitanen S, Hou K, Hamburg S, Baer MR (2018) Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. J Hematol Oncol 11(1):101. https:\/\/doi.org\/10.1186\/s13045-018-0642-0","journal-title":"J Hematol Oncol"},{"issue":"5","key":"4002_CR48","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood-2018-02-785923","volume":"132","author":"A Pardanani","year":"2018","unstructured":"Pardanani A, Tefferi A (2018) How I treat myelofibrosis after failure of JAK inhibitors. Blood 132(5):492\u2013500. https:\/\/doi.org\/10.1182\/blood-2018-02-785923","journal-title":"Blood"},{"issue":"4","key":"4002_CR49","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, investigators C-I (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100(4):479\u2013488. https:\/\/doi.org\/10.3324\/haematol.2014.115840","journal-title":"Haematologica"},{"issue":"25","key":"4002_CR50","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, investigators C-I (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047\u20134053. https:\/\/doi.org\/10.1182\/blood-2013-02-485888","journal-title":"Blood"},{"issue":"8","key":"4002_CR51","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","volume":"20","author":"SC Meyer","year":"2014","unstructured":"Meyer SC, Levine RL (2014) Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 20(8):2051\u20132059. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0279","journal-title":"Clin Cancer Res"},{"issue":"7414","key":"4002_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","volume":"489","author":"P Koppikar","year":"2012","unstructured":"Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, G\u00f6nen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL (2012) Heterodimeric JAK\u2013STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489(7414):155\u2013159. https:\/\/doi.org\/10.1038\/nature11303","journal-title":"Nature"},{"issue":"1","key":"4002_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood.V95.1.19","volume":"95","author":"AC Ward","year":"2000","unstructured":"Ward AC, Touw I, Yoshimura A (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95(1):19\u201329","journal-title":"Blood"},{"issue":"3","key":"4002_CR54","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12185-016-2130-z","volume":"105","author":"N Komatsu","year":"2017","unstructured":"Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K (2017) Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. Int J Hematol 105(3):309\u2013317. https:\/\/doi.org\/10.1007\/s12185-016-2130-z","journal-title":"Int J Hematol"},{"issue":"1","key":"4002_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"AJ Mead","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C (2015) Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial. Br J Haematol 170(1):29\u201339. https:\/\/doi.org\/10.1111\/bjh.13379","journal-title":"Br J Haematol"},{"issue":"3","key":"4002_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00277-016-2884-7","volume":"96","author":"M Breccia","year":"2017","unstructured":"Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, Centra A, Villiva N, Celesti F, Trawinska MM, Massaro F, Di Veroli A, Anaclerico B, Colafigli G, Molica M, Spadea A, Petriccione L, Cimino G, Latagliata R (2017) Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Ann Hematol 96(3):387\u2013391. https:\/\/doi.org\/10.1007\/s00277-016-2884-7","journal-title":"Ann Hematol"},{"key":"4002_CR57","first-page":"Abstract 4204","volume":"130","author":"HK Al-Ali","year":"2017","unstructured":"Al-Ali HK, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, Le Coutre P, Garcia-Hernandez C, Zaritskey A, Tavares R, Griesshammer M, Gupta V, Raanani P, Giraldo P, Bouard C, Ronco JP, Tiwari R, Mannelli F, Vannucchi AM (2017) Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 2233). Blood 130:Abstract 4204","journal-title":"Blood"},{"issue":"9","key":"4002_CR58","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM (2016) Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 101(9):1065\u20131073. https:\/\/doi.org\/10.3324\/haematol.2016.143677","journal-title":"Haematologica"},{"key":"4002_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OTT.S53348","volume":"7","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA (2013) Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 7:13\u201321. https:\/\/doi.org\/10.2147\/OTT.S53348","journal-title":"Onco Targets Ther"},{"issue":"1","key":"4002_CR60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O\u2019Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013) Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6(1):81. https:\/\/doi.org\/10.1186\/1756-8722-6-81","journal-title":"J Hematol Oncol"},{"issue":"12","key":"4002_CR61","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1002028","journal-title":"N Engl J Med"},{"issue":"5","key":"4002_CR62","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3324\/haematol.2018.204602","volume":"104","author":"AM Vannucchi","year":"2019","unstructured":"Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H (2019) EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica 104(5):947\u2013954. https:\/\/doi.org\/10.3324\/haematol.2018.204602","journal-title":"Haematologica"},{"issue":"12","key":"4002_CR63","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86(12):1188\u20131191. https:\/\/doi.org\/10.4065\/mcp.2011.0518","journal-title":"Mayo Clin Proc"},{"issue":"29","key":"4002_CR64","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1200\/jco.2012.47.6473","volume":"31","author":"T Dai","year":"2013","unstructured":"Dai T, Friedman EW, Barta SK (2013) Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 31(29):e430\u2013e432. https:\/\/doi.org\/10.1200\/jco.2012.47.6473","journal-title":"J Clin Oncol"},{"issue":"5","key":"4002_CR65","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s12185-014-1628-5","volume":"100","author":"Y Beauverd","year":"2014","unstructured":"Beauverd Y, Samii K (2014) Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol 100(5):498\u2013501. https:\/\/doi.org\/10.1007\/s12185-014-1628-5","journal-title":"Int J Hematol"},{"issue":"8","key":"4002_CR66","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ajh.24775","volume":"92","author":"G Coltro","year":"2017","unstructured":"Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM (2017) A life-threatening ruxolitinib discontinuation syndrome. Am J Hematol 92(8):833\u2013838. https:\/\/doi.org\/10.1002\/ajh.24775","journal-title":"Am J Hematol"},{"issue":"4","key":"4002_CR67","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"G Wernig","year":"2008","unstructured":"Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13(4):311\u2013320. https:\/\/doi.org\/10.1016\/j.ccr.2008.02.009","journal-title":"Cancer Cell"},{"key":"4002_CR68","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.13167.1","volume":"7","author":"W Vainchenker","year":"2018","unstructured":"Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN (2018) JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research 7:82. https:\/\/doi.org\/10.12688\/f1000research.13167.1","journal-title":"F1000Research"},{"issue":"12","key":"4002_CR69","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0091270010389469","volume":"51","author":"JG Shi","year":"2011","unstructured":"Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S (2011) The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 51(12):1644\u20131654. https:\/\/doi.org\/10.1177\/0091270010389469","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"4002_CR70","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","volume":"33","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A (2009) The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 33(9):1199\u20131203. https:\/\/doi.org\/10.1016\/j.leukres.2009.01.035","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"4002_CR71","doi-asserted-by":"publisher","first-page":"S356","DOI":"10.1016\/j.clml.2019.07.375","volume":"19","author":"C Harrison","year":"2019","unstructured":"Harrison C, Schaap N, Vannucchi A, Kiladijan JJ, Jourdan E, Silver R, Schouten H, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Gerike T, Rose S, Li M, Berry T, Brownstein C, Mesa R (2019) Fedratinib induces spleen responses in patients with myeloproliferative neoplasm (MPN)-associated intermediate- or high-risk myelofibrosis (MF) resistant or intolerant to ruxolitinib: an updated analysis of the phase II JAKARTA2 study. Clin Lymphoma Myeloma Leuk 19(Suppl 1):S356","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4002_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.63","volume":"5","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M (2015) A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 5:e335. https:\/\/doi.org\/10.1038\/bcj.2015.63","journal-title":"Blood Cancer J"},{"issue":"2","key":"4002_CR73","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00000441-200202000-00010","volume":"323","author":"PR Ogershok","year":"2002","unstructured":"Ogershok PR, Rahman A, Nestor S, Brick J (2002) Wernicke encephalopathy in nonalcoholic patients. Am J Med Sci 323(2):107\u2013111","journal-title":"Am J Med Sci"},{"issue":"2","key":"4002_CR74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/bjh.14128","volume":"178","author":"N Curto-Garcia","year":"2017","unstructured":"Curto-Garcia N, Harrison CN, McLornan DP, Radia DH (2017) Thiamine deficiency appears uncommon in patients with myeloproliferative neoplasms. Br J Haematol 178(2):338\u2013340. https:\/\/doi.org\/10.1111\/bjh.14128","journal-title":"Br J Haematol"},{"issue":"7","key":"4002_CR75","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789\u2013796. https:\/\/doi.org\/10.1200\/JCO.2010.32.8021","journal-title":"J Clin Oncol"},{"issue":"s1","key":"4002_CR76","first-page":"abstract 0361","volume":"97","author":"J Gotlib","year":"2012","unstructured":"Gotlib J, Pardanani A, Jamieson C, Cortes J, Talpaz M, Stone R, Gao G, Zhang J, Neumann F, Lebedinsky C, Tefferi A (2012) Long-term follow up of a phase 1\/2 study of SAR302503, an oral JAK2 selective inhibitor, in patients with myelofibrosis (MF). Haematologica 97(s1):abstract 0361","journal-title":"Haematologica"},{"issue":"11","key":"4002_CR77","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1038\/bcj.2011.43","volume":"1","author":"S Hart","year":"2011","unstructured":"Hart S, Goh KC, Novotny-Diermayr V, Tan YC, Madan B, Amalini C, Ong LC, Kheng B, Cheong A, Zhou J, Chng WJ, Wood JM (2011) Pacritinib (SB1518), a JAK2\/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J 1(11):e44. https:\/\/doi.org\/10.1038\/bcj.2011.43","journal-title":"Blood Cancer J"},{"issue":"S1","key":"4002_CR78","doi-asserted-by":"publisher","first-page":"abstract 667","DOI":"10.1182\/blood-2019-129293","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Savona MR, SCott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi AM, Mead AJ, O\u2019Sullivan J, Buckley SA, Mould DR, Tyavanagimatt S, Smith JA, Mascarenhas J (2019) Results of PAC203: a randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib. Blood 134(S1):abstract 667","journal-title":"Blood"},{"issue":"1","key":"4002_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87(1):25\u201333. https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.001","journal-title":"Mayo Clin Proc"},{"issue":"s1","key":"4002_CR80","first-page":"abstract 634","volume":"134","author":"RA Mesa","year":"2019","unstructured":"Mesa RA, Talpaz M, Kiladjian JJ, Harrison CN, Verstovsek S, Buckley SA, Roman-Torres K, Mascarenhas J (2019) Pacritinib demonstrates efficacy versus best available therapy in myelofibrosis patients with severe thrombocytopenia in two phase 3 studies. Blood 134(s1):abstract 634","journal-title":"Blood"},{"issue":"13","key":"4002_CR81","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, Seifert M, Posch W, Nairz M, Maciejewski P, Fowles P, Burns CJ, Smith G, Wagner KU, Weiss G, Whitney JA, Theurl I (2017) Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood 129(13):1823\u20131830. https:\/\/doi.org\/10.1182\/blood-2016-09-740092","journal-title":"Blood"},{"issue":"4","key":"4002_CR82","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/leu.2017.330","volume":"32","author":"A Pardanani","year":"2018","unstructured":"Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A (2018) Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia 32(4):1035\u20131038. https:\/\/doi.org\/10.1038\/leu.2017.330","journal-title":"Leukemia"},{"issue":"6","key":"4002_CR83","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s11899-017-0403-0","volume":"12","author":"K Pettit","year":"2017","unstructured":"Pettit K, Odenike O (2017) Novel therapies for myelofibrosis. Curr Hematol Malig Rep 12(6):611\u2013624. https:\/\/doi.org\/10.1007\/s11899-017-0403-0","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-04002-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:25:43Z","timestamp":1616199943000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-04002-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["4002"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04002-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CNH received research fees from Novartis and speaker payments from Novartis, Celgene, Roche, and Jannsen and participated in advisory boards for Sierra Oncology, Promedior, Celgene, and Novartis. RAM received consultant fees from Novartis, Sierra, and La Jolla Pharmaceutical Company and received research support from Celgene, Incyte, Abbvie, Samus Therapeutics, Genotech, Promedior, and CTI Biopharma. NC declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}